

09/936316
533 Rec'd PCT/PTO 10 SEP 2001

Practitioner's Docket No.: RWS-80019

CHAPTER II

"Express Mail" mailing label number EL758655743US
Date of Deposit September 10, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Michael Burns
MICHAEL BURNS

**TRANSMITTAL LETTER
TO THE UNITED STATES ELECTED OFFICE (EO/US)
(ENTRY INTO U.S. NATIONAL PHASE UNDER CHAPTER II)**

INTERNATIONAL APPLICATION NO. PCT/EP00/02191	INTERNATIONAL FILING DATE 09 March 2000	PRIORITY DATE 09 March 1999
TITLE OF INVENTION SPHINGOID BASE DERIVATIVES AND USES THEREOF		
APPLICANT STREEKSTRA, Hugo et al.		

Box PCT
Assistant Commissioner for Patents
Washington D.C. 20231
ATTENTION: EO/US

1. Applicant herewith submits to the United States Elected Office (EO/US) the following items under 35 U.S.C. 371:
 - a. ☒ This express request to immediately begin national examination procedures (35 U.S.C. 371(f)).
 - b. ☒ The U.S. National Fee (35 U.S.C. 371(c)(1)) and other fees (37 C.F.R. § 1.492) as indicated below:

*See attached Preliminary Amendment Reducing the Number of Claims.

- i. ☒ Counsel's payment in the amount of \$940.00 to cover the above fees is enclosed.
 - ii. ☐ Please charge Account No. _____ in the amount of \$ _____.
A duplicate copy of this sheet is enclosed.
3. ☒ A copy of the International application as filed (35 U.S.C. 371(c)(2)):
- a. ☒ is transmitted herewith.
 - b. ☐ is not required, as the application was filed with the United States Receiving Office.
 - c. ☐ has been transmitted
 - i. ☐ by the International Bureau.
Date of mailing of the application (from form PCT/IB/308): _____.
 - ii. ☐ by applicant on _____.
Date
4. ☒ A translation of the International application into the English language (35 U.S.C. 371(c)(2)):
- a. ☐ is transmitted herewith.
 - b. ☒ is not required as the application was filed in English.
 - c. ☐ was previously transmitted by applicant on _____.
Date
 - d. ☐ will follow.
5. ☐ Amendments to the claims of the International application under PCT Article 19 (35 U.S.C. 371(c)(3)):
- a. ☐ are transmitted herewith.
 - b. ☐ have been transmitted
 - i. ☐ by the International Bureau.
Date of mailing of the amendment (from form PCT/IB/308): _____.
 - ii. ☐ by applicant on _____.
Date
 - c. ☐ have not been transmitted as
 - i. ☐ applicant chose not to make amendments under PCT Article 19.
Date of mailing of Search Report (from form PCT/ISA/210): _____.
 - ii. ☐ the time limit for the submission of amendments has not yet expired. The amendments or a statement that amendments have not been made will be transmitted before the expiration of the time limit under PCT Rule 46.1.
6. ☐ A translation of the amendments to the claims under PCT Article 19 (38 U.S.C. 371(c)(3)):
- a. ☐ is transmitted herewith.
 - b. ☐ is not required as the amendments were made in the English language.
 - c. ☐ has not been transmitted for reasons indicated at point 5(c) above.

0936316

7. ☒ A copy of the international examination report (PCT/IPEA/409)
☒ is transmitted herewith.
☐ is not required as the application was filed with the United States Receiving Office.
8. ☐ Annex(es) to the international preliminary examination report
a. ☐ is/are transmitted herewith.
b. ☐ is/are not required as the application was filed with the United States Receiving Office.
9. ☐ A translation of the annexes to the international preliminary examination report
a. ☐ is transmitted herewith.
b. ☐ is not required as the annexes are in the English language.
10. ☒ An oath or declaration of the inventor (35 U.S.C. 371(c)(4)) complying with 35 U.S.C. 115
a. ☐ was previously submitted by applicant on _____.
Date
b. ☒ is submitted herewith, and such oath or declaration
i. ☒ is attached to the application.
ii. ☐ identifies the application and any amendments under PCT Article 19 that were transmitted as stated in points 3(b) or 3(c) and 5(b); and states that they were reviewed by the inventor as required by 37 C.F.R. 1.70.
iii. ☐ will follow.

Other document(s) or information included:

11. ☒ An International Search Report (PCT/ISA/210) or Declaration under PCT Article 17(2)(a):
a. ☒ is transmitted herewith.
b. ☐ has been transmitted by the International Bureau.
Date of mailing (from form PCT/IB/308): _____.
c. ☐ is not required, as the application was searched by the United States International Searching Authority.
d. ☐ will be transmitted promptly upon request.
e. ☐ has been submitted by applicant on _____.
Date
12. ☐ An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98:
a. ☐ is transmitted herewith.
Also transmitted herewith is/are:
☐ Form PTO-1449 (PTO/SB/08A and 08B).
☐ Copies of citations listed.
b. ☐ will be transmitted within THREE MONTHS of the date of submission of requirements under 35 U.S.C. 371(c).
c. ☐ was previously submitted by applicant on _____.
Date

202310" STEEE660

Docket No.: RWS-80019

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : STREEKSTRA, Hugo et al.

Applic. No.: PCT/EP00/02191

Filed : March 9, 2000

Title : SPHINGOID BASE DERIVATIVES AND USES THEREOF

P R E L I M I N A R Y A M E N D M E N T

Hon. Commissioner of Patents,
Washington, D. C. 20231

S i r :

Preliminary to examination kindly amend the above-identified
application as follows:

In the Claims:

Claim 10 (amended). The composition of claim 8 comprising the
sphingoid base derivative in a concentration ranging from
0.001 to 5 wt %, preferably from 0.005 to 5 wt %, more
preferably from 0.01 to 2.5 wt %, most preferably from 0.02 to
1 wt %, especially preferably from 0.02 to 0.5 wt %.

Remarks:

The preliminary amendment is being filed in an effort to
eliminate multiple dependencies in the claims.

09/936210


518 Rec'd PCT/PTO 10 SEP 2001

13. ☐ An assignment document is transmitted herewith for recording.

A separate ☐ "COVER SHEET FOR ASSIGNMENT (DOCUMENT) ACCOMPANYING
NEW PATENT APPLICATION" or ☐ FORM PTO
1595 is also attached.

14. ☒ Additional documents:
- a. ☐ Copy of request (PCT/RO/101)
 - b. ☒ International Publication No. WO 00/53568
 - i. ☒ Specification, claims and drawing
 - ii. ☐ Front page only
 - c. ☒ Preliminary amendment (37 C.F.R. § 1.121)
 - d. ☐ Other

15. ☒ The above checked items are being transmitted
- a. ☒ before 30 months from any claimed priority date.
 - b. ☐ after 30 months.


SIGNATURE OF PRACTITIONER

September 10, 2001

Lerner and Greenberg, P.A.
P.O. Box 2480
Hollywood, Florida 33020-2480
Tel.: (954) 925-1100
Fax: (954) 925-1101

LAURENCE A. GREENBERG
REG. NO. 28,602

09936316-012202

09/936316

518 Rec'd PCT/PTO 10 SEP 2001

An early action on the merits of the claims is requested.

Respectfully submitted,


For Applicant

LAURENCE A. GREENBERG
REG. NO. 92578

/tk

September 10, 2001

Lerner and Greenberg, P.A.
P.O. Box 2480
Hollywood, Florida 33022-2480
Tel.: (954) 925-1100
Fax: (954) 925-1101

09/936316

[illegible][illegible]

SPHINGOID BASE DERIVATIVES AND USES THEREOF

5

Field of the invention

The present invention relates to the field of topical application, especially topical application of sphingoid base derivatives.

10

Background of the invention

Sphingoid bases like sphingosine are known to be potent effectors of skin cell differentiation and proliferation, by interfering with basic biochemical cell processes (Hannun, Y.A. and Bell, R.M. (1989), Science 243, 500-507). For example, free sphingosine inhibits the activity of protein kinase C and thus plays a pivotal role in signal transduction and regulation of cell division (Hannun, Y.A. et al. (1986), J. Biol. Chem. 261, 12604-12609). The action of free sphingosine may be an important factor in the modulation of epidermal cell proliferation in order to balance the rate in which cells are lost from the skin surface (Downing, D.T. (1992) J. Lipid Res., 33, 301-313). In addition, other biological activities have been described for sphingoid bases, such as antimicrobial activity (Bibel, D.E. et al. (1992), J. Invest. Dermatol. 98, 269-273).

Due to their effect on skin cell differentiation and proliferation and their antimicrobial activity, sphingoid bases may be included as an active ingredient in various cosmetic compositions. For example, sphingosine has been described for the treatment of various abnormalities and disorders concerning the skin, such as dry skin, xeroderma and psoriasis. Sphingosine can also protect the skin against various harmful or undesirable effects, such as the effects of UV light and skin ageing. In particular, sphingoid bases have been included in topical compositions as an antiinflammatory agent or an antimicrobial agent (WO98/49999).

A disadvantage of sphingoid bases is their scarce solubility in an aqueous environment. This phenomenon hampers the use of these compounds in aqueous formulations. For instance, to display an effective antimicrobial activity, it is important to have the sphingoid base solubilized in an aqueous formulation.

Description of the invention

The present invention discloses derivatives of sphingoid bases which have a substantially increased solubility in water than their free base counterparts. As a consequence, these sphingoid base derivatives display a surprisingly improved efficacy when formulated in an aqueous composition.

The sphingoid base derivatives of the invention are salts of sphingoid bases.

According to the invention, the anion of a sphingoid base salt is derived from any suitable acid. In that regard, a suitable acid is defined as an acid which, upon mixing with a sphingoid base in a suitable solvent, produces a salt which has an increased solubility in an aqueous medium as compared to the solubility of the sphingoid base as such.

In one embodiment of the invention, the acid is an acid which itself may have an efficacy in topical application.

In one embodiment of the invention, the acid is a hydrophilic acid able to deliver the sphingoid base to the water phase of a cosmetic or pharmaceutical composition.

Preferably, the acid is a hydrophilic organic acid such as an α -hydroxy alcanoic acid, a β -hydroxy alcanoic acid, an α,β -dihydroxy alcanoic acid, an alkanedioic acid or a mineral acid. More preferred examples of hydrophilic organic acids are lactic acid, glycolic acid, malic acid, pyruvic acid, succinic acid, fumaric acid, citric acid, ascorbic acid, gluconic acid and/or pyroglutamic acid (pyrrolidone carboxylic acid). More preferred examples of mineral acids are hydrochloric acid, nitric acid and/or phosphoric acid.

In another embodiment of the invention, the acid is a lipophilic organic acid, such that the combination with a sphingoid base increases the efficacy of both the lipophilic acid as well as the sphingoid base.

The sphingoid base salts of the invention may be prepared as follows. The sphingoid base is dissolved in a suitable organic solvent, whereupon at least one equivalent of a suitable acid is added. Typically, addition of the acid will result in a decrease in the pH of at least about 3 units. It is appreciated that the final value of the pH will be dependent on the acid being applied. Dissolution of the sphingoid base in the organic solvent preferably occurs at an elevated temperature, for instance a temperature of 50°C to 70°C. Upon cooling of the

mixture, the sphingoid base salt will precipitate. The crystalline precipitate is recovered from the reaction mixture by filtration and optionally may be washed with solvent, preferably the same solvent as being used for preparation of the salt.

5 A suitable organic solvent preferably is a solvent wherein the end product, i.e. the sphingoid base salt, is insoluble. A suitable organic solvent for instance is ethanol or methyl isobutyl ketone.

 In one embodiment of the invention, a sphingoid base salt is used as a starting compound for the preparation of another sphingoid base salt.

10 It is essential that the sphingoid base salts of the invention are prepared prior to their intended use, e.g. their inclusion in a topical composition. The inclusion of a free sphingoid base in a topical composition additionally containing anions from one or more of the acids as defined herein above will not result in an increased solubility and/or an increased efficacy.

15 The sphingoid base salts of the invention preferably are salts of the sphingoid bases sphingosine, sphinganine or phytosphingosine. More preferably, the sphingoid base salts are salts of phytosphingosine.

 In one embodiment of the invention, phytosphingosine is obtained via a microbial fermentation. For instance, phytosphingosine is obtained from *Pichia ciferrii*-derived tetraacetyl-phytosphingosine (TAPS), by a suitable deacetylation reaction. The deacetylation may be chemical, e.g. by base catalyzed hydrolysis with potassium hydroxide, or enzymatical. After alkaline hydrolysis of TAPS, the resulting phytosphingosine may be purified. Such a purification can occur by any method known to a person skilled in the art. Yeast-derived phytosphingosine is
20 human skin-identical, as it is reported to have the same stereochemical configuration as mammalian phytosphingosine, i.e. the D-D-erythro configuration.

25 The sphingoid base salts of the invention have a solubility in an aqueous environment which is considerably higher than the solubility of the free sphingoid base. It is further surprisingly shown by the present invention that sphingoid base salts have an increased efficacy as compared to the free sphingoid base,
30 even in an environment where the free sphingoid base also is in a solubilised form. The free sphingoid base may be in a solubilised form by the additional presence in the aqueous medium of an organic solvent and a surface active compound.

Compositions comprising a sphingoid base derivative according to the invention are suitable for topical application, whereby topical application is understood to comprise cosmetic and/or dermatological application on the skin, on hair and on the epithelial linings of mouth, nose, eye, urogenital tract, and the like.

The sphingoid base derivatives of the present invention preferably are incorporated in a topical composition in a concentration which may range from 0.001 to 5 wt %, preferably from 0.005 to 5 wt %, more preferably from 0.01 to 2.5 wt %, most preferably from 0.02 to 1 wt %, especially preferably from 0.02 to 0.5 wt %.

Topical compositions including a sphingoid base derivative according to the invention are particularly suitable to apply to various topically occurring undesirable and/or abnormal conditions associated with inflammation and/or microbial activity.

Examples of topically occurring undesirable and/or abnormal conditions to which topical compositions comprising the sphingoid base derivatives of the invention are advantageously applied are eczema, psoriasis, atopic dermatitis, acne, dandruff, mouth and/or lip infections, mycoses, various other skin-infectious diseases or vaginal infections. Topical compositions comprising said sphingoid base derivatives are further advantageously applied for wound-healing, e.g. in case of burns, and for normalisation of skin flora.

Due to their antimicrobial activity, the sphingoid base derivatives of the invention additionally may function as a preservative in cosmetic and dermatological compositions, to decrease and/or substitute for existing chemical preservatives.

Example 1

Preparation of PS.lactate

A mixture of 50 grams of phytosphingosine and 500 ml of absolute ethanol was stirred and heated to 65°C. Next the almost clear solution was filtered while hot through a paper filter into a 1 litre 3-necked flask.

While stirring (L)-lactic acid (25.7 g) was added to the filtrate in portions to decrease the pH from 9.9 to 5.3, while the temperature went up from 66°C

to 71°C. The mixture was stirred and cooled. At ca 45°C crystallisation started, while cooling was continued over a period of 3/4 hour to 21°C.

The precipitate was filtered off and the cake was replaced with 150 ml of ethanol (fast filtration and replacing, total of 2 minutes).

5 The wet cake (110.8 g) was dried under vacuum to give 51.2 grams of product. NMR analysis gave a purity of 99.3%.

Example 2

Preparation of PS.glycolate

10

A mixture of 50 grams of phytosphingosine and 500 ml of absolute ethanol was stirred and heated to 65°C. Next the almost clear solution was filtered while hot through a paper filter into a 1 litre 3-necked flask. Rinsed with 20 ml of hot ethanol. The filtrate was heated again to 65°C.

15

While stirring glycolic acid (13.4 g) was added to the filtrate in portions to decrease the pH from 9.9 to 5.6, while the temperature went up from 65°C to 68°C. The mixture was stirred and cooled. At ca 66°C crystallisation started, while cooling was continued over a period of 20 minutes to 25°C.

20

The precipitate was filtered off and the cake was replaced with 150 ml of ethanol (fast filtration and replacing, total of 3 minutes)

The wet cake (87 g) was dried overnight under vacuum to give 56.6 grams of product. NMR analysis gave a purity of 98.6%.

Example 3

Preparation of PS.HCl

25

30 A mixture of 50 grams of phytosphingosine and 500 ml of absolute ethanol was stirred and heated to 65°C. Next the almost clear solution was filtered while hot through a paper filter into a 1 litre 3-necked flask. Rinsed with 20 ml of hot ethanol.

While stirring hydrochloric acid (36%, ca 13 ml) was added to the filtrate to decrease the pH from 10.3 to ca 0, while the temperature went up from 45°C to 50°C. The mixture was stirred and cooled. At 34°C crystallisation started after seeding and cooling was continued over a period of 0.5 hour to 10°C.

5

Example 4

Preparation of PS.pyroglutamate

Next 12 grams of DL-pyroglutamic acid were added, changing the pH from 9.4 to 5.8

Next the mixture was further cooled to 17 °C and filtered over a glass G3 filter, rinsed / replaced with 50 ml of fresh MIK (fast filtration). The wet cake (57 g) was dried in vacuum to give 34.3 grams of product.

20

Example 5

Preparation of PS.citrate

25

Next 18 grams of citric acid monohydrate were added, changing the pH from 9.4 to 1.8

A precipitate was obtained. Next the mixture was cooled to 14 °C and filtered over a glass G3 filter, rinsed / replaced with 50 ml of fresh MIK (fast filtration). The wet cake (84 g) was dried in vacuum to give 39.7 grams of product. NMR analysis gave a purity of 96.4 %.

Example 6**Antimicrobial activity of PS against yeasts**

Two different yeast strains were used: *Saccharomyces cerevisiae* ATCC
5 9763 and *Candida albicans* ATCC 10231. All incubations were either performed
at 30°C (for *S. cerevisiae*) or at 37°C (for *C. albicans*). Both yeast strains were
grown in YEPD2% medium (20 g/l glucose, 10 g/l peptone, 20 g/l yeast extract,
pH=6.0). The cultures were grown overnight, the cells in 50 µl of culture were
harvested by centrifugation, washed with 1 ml sterile buffer (10 mM HEPES
10 (pH= 7.2 with NaOH) + 20 g/l glucose), centrifuged, and resuspended in 0.5 ml
sterile buffer.

A 10 mg/ml stock solution of phytosphingosine (PS) was prepared in a
solvent system, consisting of 1 volume fraction ethanol, 2 volume fractions
Tween 20 and 17 volume fractions 50% glycerol in water. The components of
15 the solvent system were added to the phytosphingosine in this order, and the
solution was shaken vigorously after each addition. When all solvents had been
added, the mixture was heated to 40°C for 15 to 30 minutes. Dilutions from this
stock solution (if necessary) were made in 5% ethanol in water. All solutions
were prepared 24 hours prior to use, and kept at room temperature.

20 The antifungal effect of phytosphingosine against these two yeasts was
investigated using the LIVE/DEAD® Yeast Viability Kit L-7009 (Molecular Probes
Inc., Oregon, USA). This kit employs two different fluorescent stains, FUN-1™
and Calcofluor™ White M2R, to make distinction between living and dead cells,
which can be observed using a fluorescence microscope with the appropriate
25 filters.

For this analysis, the following amounts of fluorescent dyes were added
to 0.5 ml yeast cell suspension in sterile buffer, prepared as described
previously: 1 µl FUN-1™ and 2.5 µl Calcofluor™ White M2R. After mixing, these
suspensions were incubated for 30 minutes. Then 50 µl of an appropriate
30 dilution of the phytosphingosine stock solution were added, to obtain the final
concentrations indicated in Figures 1a and 1b. After mixing, these suspensions
were incubated, and the fraction of living and dead cells was followed over time.

An Olympus BHB fluorescence microscope was used for the microscopic
observations, with two different filter sets:

1. Dichroic mirror blue (B), excitation filter IF490, emission filter O530 (living cells show orange particles in the cell, whereas dead cells are evenly coloured green/orange).
- 5 2. Dichroic mirror violet (V), excitation filters U95-B93, emission filter Y455 (living cells show blue cell walls, whereas dead cells do not).

The results are shown in Figure 1a and 1b. It is clear that both yeast strains were killed by phytyphingosine (PS) in a dose-dependent fashion.

10

Example 7

Antifungal action of PS towards starved cells

In their natural habitat, microbial cells are in a starved condition for most of the time. This prompted us to investigate whether the antimicrobial action of PS would also be manifest against starving cells.

To this end, the procedure described in Example 6 was slightly modified (all methods and conditions were identical unless specified otherwise). Cells from an overnight culture of *Candida albicans* ATCC 10231 were harvested by centrifugation. Two different buffers were used to wash and resuspend the cells: 10 mM HEPES (pH = 7.2 with NaOH) + 20 g/l glucose as used in Example 6, and the same buffer without glucose.

The two cell suspensions, with and without glucose (2.5 ml for each condition), were incubated for 10 minutes at 37°C. Then 125 µl of an appropriate dilution of the phytosphingosine stock solution were added, to obtain the final concentrations indicated in Figure 2. After mixing, these suspensions were incubated further, and at the indicated time points 100 µl samples were drawn. The cells were harvested by centrifugation, and the cells were resuspended in 100 µl buffer with glucose, and with the same concentrations of fluorescent dyes as in Example 6. This analysis mixture was incubated for 10 minutes more, to allow the dyes to be taken up into the cells, and the numbers of living and dead cells were determined as described in Example 6.

As is shown in Figure 2, the starved cells were more susceptible to the antifungal action of PS than were the energised cells. In fact, after an initial lag

093316 012200 202210 973360

phase, 250 mg/l PS proved to be as effective in killing the starved cells as 500 mg/l. The lag phase is presumably due to the presence of endogenous energy stores of the cells, and this again shows that PS is particularly effective towards the starved condition.

5

Example 8

Antibacterial effect of PS in cosmetic preparations in an agar diffusion test

An overnight culture of *Staphylococcus aureus* ATCC 14458 was prepared similarly to the procedure described in Example 6 (BHI medium (Difco), incubation at 37°C).

To prepare agar plates for the diffusion test, 300 ml of BHI medium, with 1% agar and 15% glycerol added, was molten and cooled to 50°C. Then 6 ml of a sterile glucose solution (50% w/v) and 6 ml of the overnight culture of the micro-organism were added. Petri dishes were filled with 12.5 ml of this agar medium, and the medium was allowed to solidify.

The test formulations were prepared as indicated in Figure 6, with a lipid phase of octyl dodecyl lactate. They contained 1, 2 or 5 g/l PS.

To apply a test sample to the test plates, a stainless steel ring (6 mm internal diameter) was put into an empty, sterile Petri dish. Inside this ring, 2 paper disks (6 mm diameter) were placed to cover the bottom, and 50 µl of the test formulation was applied to the filter disks. The rings were put on the surface of the agar plates containing the micro-organisms, the agar plates were stored at 5°C for the periods indicated in the Table to allow diffusion of the test solutions, after which the rings were removed. Subsequently, the agar plates were incubated at a temperature suitable for the growth of the micro-organisms (37°C). After the micro-organisms were fully grown in the non-inhibited areas of the agar plates, the degree of inhibition was measured as the zone of no growth (or diminished growth) extending from the area of application in two orthogonal directions.

30

0936316 012209

Table 1. Antibacterial effect of PS in a cosmetic preparation

[PS] (g/l)	Diffusion 5 days 5°C			Diffusion 14 days 5°C		
1	-	-	-	-	-	-
2	7	6	5	7/14	7/13	5/11
5	5	6.5	7	7.5/14	9.5/16	9/15

Where two figures are given, the first refers to the zone of no-growth, whereas the second refers to the zone of diminished growth.

5

As appears from Table 1, there is a dose-dependent growth inhibition by PS.

Example 9

10

Antifungal action of PS and some of its derivatives

15

It was found that some derivatives of phytosphingosine had an improved solubility in aqueous systems. This prompted us to compare their antimicrobial activity to that of PS itself. The following derivatives were investigated: the glycolic acid, lactic acid and hydrochloric acid salts of phytosphingosine. Stock solutions of the phytosphingosine salts were prepared as described in Example 6 for phytosphingosine, and the same experimental conditions were used.

20

It was found that all three salts tested had a much stronger antifungal activity than had the free base. This was not due to the anions present in the salt solutions, since blanks with the appropriate amounts of lactate, chloride or glycolate were without effect (Figure 3a). In Figure 3b it can be seen that the potency of the chloride was more than 2.5 times higher than that of the PS base.

25

Example 10

Antifungal action of PS and some of its derivatives in a solvent-free system

Solutions in demineralised water were prepared similarly to the procedure described for the solvent system (Example 6), including the final heating step.

In Figure 4a it can be seen that the lack of solvents during sample preparation all but abolished the antifungal effect of the free PS base, whereas the potency of the PS salts was not decreased. In fact, it was found that the potency of the PS salts can even be higher in the solvent-free system, as is shown in Figures 4b and 4c.

Example 11

Antibacterial effect of PS against bacteria

10

Two different bacterial strains were used: *Staphylococcus aureus* ATCC 14458 and *Escherichia coli* 421. All incubations were performed at 37°C. Both bacteria were grown as described in Example 8, 50 µl culture was harvested by centrifugation, washed with 1 ml sterile demineralised water, and resuspended in 0.5 ml sterile demineralised water.

15

A 10 mg/ml stock solution of PS was prepared as described previously. Dilutions from this stock solution (if necessary) were made in 5% ethanol in water. All solutions were prepared 24 hours prior to use, and kept at room temperature.

20

The antibacterial effect of phytosphingosine against these two bacteria was investigated using the LIVE/DEAD® BacLight™ Bacterial Viability Kit L-7012 (Molecular Probes Inc., Oregon, USA). This kit employs two different fluorescent stains, SYTO 9 stain and propidium iodide, to make distinction between living and dead cells, which can be observed using a fluorescence microscope with the appropriate filters.

25

The solutions of the dyes provided in the kit were mixed 1:1 just before use, and 1.5 µl of this fluorescent dye mixture was added to 0.5 ml bacterial suspension. Subsequently, 50 µl of an appropriate dilution of the phytosphingosine stock solution were added, to obtain the final concentrations indicated in Figure 5. After mixing, these suspensions were incubated, and the fraction of living and dead cells were followed over time.

30

The microscopic examinations were performed using an Olympus BHB fluorescence microscope, with the following filter set: dichroic mirror blue (B),

excitation filter IF490, emission filter O530 (living cells are green, dead cells are orange/yellow).

It was found that *S. aureus* was strongly killed. However, this effect could not be quantified, since the dead cells were not detectable, due to lysis: the measurement with fluorescent dyes requires that the dead cell remains structurally intact. Therefore, the killing effect was apparent only in a strong decrease in the number of living cells.

The *E. coli* cells were also killed quite effectively, and in this organism the dead cells could be quantified readily (Figure 5). It appears that the cells are killed by PS in a dose-dependent manner, and that the bacteria are more sensitive to this compound than are the fungi.

Example 12

Antibacterial and antifungal effect of PS derivatives in a diffusion test

An overnight culture of the indicated test organisms was prepared as described in Example 6 and 8, and the samples were applied to the test plates as described in Example 8. The samples were prepared as the appropriate dilutions from stock solutions, prepared as described previously. The agar plates were stored overnight at 5°C to allow diffusion on the test solutions, after which the sample rings were removed. Subsequently, the agar plates were incubated at a temperature suitable for the growth of the micro-organisms (37°C). After the micro-organisms were fully grown in the non-inhibited areas of the agar plates, the degree of inhibition was measured as the zone of no growth (or diminished growth) extending from the area of application in two orthogonal directions (in mm).

Table 2. Antibacterial and antifungal effects of PS-derivatives in an agar diffusion test

Derivative	(g/l)	S. aureus ATCC 14456			C. albicans ATCC10231		
PS-lactate	10	12	13	13	9*	9.5*	10.5*
	5	12	10.5	12	8*	9*	9*
	2	8	8.5	9	±	5*	5*
	1	6	5	5	4*	6*	4*
PS-glycolate	10	11.5	9.5	11	7.5	5*	6
	5	9	9	9	3	3	3
	2	7	6	5	-	-	-
	1	3	4.5	3	-	-	-
PS-chloride	10	12.5	11	11	7	6*	7
	5	9	9	9	2	3	3
	2	6	7	5	-	-	-
	1	5	5	5	-	-	-

* The data marked with an asterisk refer to a zone of inhibited growth; the unmarked data refer to zones of no growth.

It appears from Table 2 that the PS derivatives are fully active against bacteria and fungi in the diffusion test, and that there is a clear dose dependency of this effect.

CLAIMS

1. A sphingoid base derivative which is a salt of a sphingoid base.
- 5 2. The sphingoid base derivative of claim 1, wherein the anion of the salt is derived from a hydrophilic acid.
3. The sphingoid base derivative of claim 2, wherein the hydrophilic acid is a
10 hydrophilic organic acid or a mineral acid.
4. The sphingoid base derivative of claim 3, wherein the hydrophilic acid is selected from the group consisting of lactic acid, glycolic acid, malic acid, pyruvic acid, succinic acid, fumaric acid, citric acid, ascorbic acid, gluconic
15 acid and pyroglutamic acid.
5. The sphingoid base derivative of claim 3, wherein the hydrophilic acid is selected from the group consisting of lactic acid, glycolic acid, pyroglutamic acid, citric acid and hydrochloric acid.
20
6. A process for the preparation of the sphingoid base derivative of claim 1 comprising the addition of at least one equivalent of an acid to a solution of the sphingoid base in a suitable solvent and the recovery of the crystalline sphingoid base salt from the reaction mixture.
25
7. The process of claim 6, wherein the solvent is ethanol or methyl isobutyl ketone.
8. A composition for topical use comprising the sphingoid base derivative of
30 claim 1.
9. The composition of claim 8 which is a cosmetic composition.

10. The composition of claim 8 or 9 comprising the sphingoid base derivative in a concentration ranging from 0.001 to 5 wt %, preferably from 0.005 to 5 wt %, more preferably from 0.01 to 2.5 wt %, most preferably from 0.02 to 1 wt %, especially preferably from 0.02 to 0.5 wt %.

5

11. A sphingoid base derivative according to claim 1 for use as a medicament.

12. Use of a sphingoid base derivative according to claim 1 for the manufacture of a medicament for use in antimicrobial and/or anti-inflammatory treatment.

09936316 01.02.02

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

Figure 1a. Antifungal effect of PS
against *S. cerevisiae*





Figure 1b. Antifungal effect of PS
against *C. albicans*






Figure 3a. Comparison of PS and its salts
against *C. albicans*




Figure 3b. Comparison of potency of chloride and free base
against *C. albicans*




Figure 4a. Antifungal activity in water
against *C. albicans*





Figure 4b. High potency of PS salts in water
against *C. albicans*






Figure 5. Antibacterial effect of phytosphingosine against *E. coli*





Figure 6. Flowsheet for preparation of Phytosphingosine containing-formulation



COMBINED DECLARATION AND POWER OF ATTORNEY

(ORIGINAL, DESIGN, NATIONAL STAGE OF PCT, SUPPLEMENTAL, DIVISIONAL,
CONTINUATION, OR C-I-P)

As a below named inventor, I hereby declare that:

TYPE OF DECLARATION

This declaration is for a national stage of PCT application.

INVENTORSHIP IDENTIFICATION

My residence, post office address and citizenship are as stated below, next to my name. I believe that I am the original, first and sole inventor (*if only one name is listed below*) or an original, first and joint inventor (*if plural names are listed below*) of the subject matter that is claimed, and for which a patent is sought on the invention entitled:

TITLE OF INVENTION

SHINGOID BASE DERIVATIVES AND USES THEREOF

SPECIFICATION IDENTIFICATION

The specification is attached hereto.

ACKNOWLEDGMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information, which is material to patentability as defined in 37, Code of Federal Regulations, § 1.56.

PRIORITY CLAIM (35 U.S.C. § 119(a)-(d))

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

Such applications have been filed as follows.

**PRIOR PCT APPLICATION(S) FILED WITHIN 12 MONTHS
(6 MONTHS FOR DESIGN) PRIOR TO THIS APPLICATION
AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. § 119(a)-(d)**

20221019 09:59:56

INDICATE IF PCT	APPLICATION NUMBER	DATE OF FILING DAY, MONTH, YEAR	PRIORITY CLAIMED UNDER 35 USC 119
PCT	PCT/EP00/02191	09 MARCH 2000	
	99200700.5	09 MARCH 1999	YES

POWER OF ATTORNEY

I hereby appoint the following practitioner(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Herbert L. Lerner
Laurence A. Greenberg
Werner H. Stemer
Ralph E. Locher

Registration Number 20435
Registration Number 29308
Registration Number 34,956
Registration Number 41,947

SEND CORRESPONDENCE TO

Lerner and Greenberg, P.A.
P.O. Box 2480
Hollywood, FL 33020-480
Tel.: (954) 925-1100
Fax: (954) 925-1101

DECLARATION

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

SIGNATURE

Full Name of First Joint Inventor: HUGO STREEKSTRA

Inventor's signature _____

Date _____

Country of Citizenship THE NETHERLANDS

Residence AMSTERDAM, THE NETHERLANDS

Post Office Address WETERINGSTRAAT 28
NL-1017 SP AMSTERDAM
THE NETHERLANDS

0936316-0120

Full Name of Second Joint Inventor: PIETER GIJSBERT WEBER

Inventor's signature _____

Date _____

Country of Citizenship THE NETHERLANDS

Residence RIDDERKERK, THE NETHERLANDS

Post Office Address STARINGLAAN 34
NL-2985 BN RIDDERKERK
THE NETHERLANDS

0906316 01290

Practitioner's Docket No.:

PATENT

COMBINED DECLARATION AND POWER OF ATTORNEY

(ORIGINAL, DESIGN, NATIONAL STAGE OF PCT, SUPPLEMENTAL, DIVISIONAL,
CONTINUATION, OR C-I-P)

As a below named inventor, I hereby declare that:

TYPE OF DECLARATION

This declaration is for a national stage of PCT application.

INVENTORSHIP IDENTIFICATION

My residence, post office address and citizenship are as stated below, next to my name. I believe that I am the original, first and sole inventor (*if only one name is listed below*) or an original, first and joint inventor (*if plural names are listed below*) of the subject matter that is claimed, and for which a patent is sought on the invention entitled:

TITLE OF INVENTION

SHINGOID BASE DERIVATIVES AND USES THEREOF

SPECIFICATION IDENTIFICATION

The specification is attached hereto.

ACKNOWLEDGMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information, which is material to patentability as defined in 37, Code of Federal Regulations, § 1.56.

PRIORITY CLAIM (35 U.S.C. § 119(a)-(d))

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

Such applications have been filed as follows.

**PRIOR PCT APPLICATION(S) FILED WITHIN 12 MONTHS
(6 MONTHS FOR DESIGN) PRIOR TO THIS APPLICATION
AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. § 119(a)-(d)**

09936316 0122002



INDICATE IF PCT	APPLICATION NUMBER	DATE OF FILING DAY, MONTH, YEAR	PRIORITY CLAIMED UNDER 35 USC 119
PCT	PCT/EP00/02191	09 MARCH 2000	
	99230700.5	09 MARCH 1999	YES

POWER OF ATTORNEY

I hereby appoint the following practitioner(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Herbert L. Lerner
Laurence A. Greenberg
Werner H. Sterner
Ralph E. Locher

Registration Number 20435
Registration Number 29308
Registration Number 34,956
Registration Number 41,947

SEND CORRESPONDENCE TO

Lerner and Greenberg, P.A.
P.O. Box 2480
Hollywood, FL 33020-480
Tel.: (954) 925-1100
Fax: (954) 925-1101

DECLARATION

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

SIGNATURE

Full Name of First Joint Inventor: **HUGO STREEKSTRA**

Inventor's signature *HUGO STREEKSTRA*

Date 25-10-2001

Country of Citizenship **THE NETHERLANDS**

Residence AMSTERDAM, **THE NETHERLANDS**

Post Office Address

**WETERINGSTRAAT 28
NL-1017 SP AMSTERDAM
THE NETHERLANDS**

200210"3T550

100

200 Full Name of Second Joint Inventor: PIETER GJSBERT WEBERInventor's signature *P. Weber*Date 9-20-2021

Country of Citizenship THE NETHERLANDS

Residence RIDDERKERK, THE NETHERLANDS

Post Office Address

STARINGLAAN 34
NL-2985 BN RIDDERKERK
THE NETHERLANDS

2022-10-01 09:41 FAX 01753480281